The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors.
D. Strumberg
Consultant or Advisory Role - Bayer; Boehringer Ingelheim (U); Lilly; Pfizer; Roche
Honoraria - Bayer; Boehringer Ingelheim; Lilly; Pfizer; Roche
B. Schultheis
No relevant relationships to disclose
U. Traugott
Consultant or Advisory Role - Silence Therapeutics
C. Vank
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
A. Santel
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
O. Keil
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
K. Giese
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
J. Kaufmann
Employment or Leadership Position - Silence Therapeutics
Stock Ownership - Silence Therapeutics
Research Funding - BMBF BioChancePlus Grant
J. Drevs
Consultant or Advisory Role - Silence Therapeutics